Brady Hunt

Brady Hunt

Auto-generated profile, based on publicly available information

Brady Hunt

Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire; Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire; Dartmouth Cancer Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2021 in Journal of Biomedical Optics
Verified
Journal Article
Open access
PDF file
BHBrady Hunt
Brady Hunt
ARAlberto J. Ruiz
Alberto J. Ruiz
BPBrian W. Pogue
Brian W. Pogue
Smartphone-based imaging (SBI) has been proposed for numerous biomedical applications, many of which use an optical attachment to augment or extend the native device capabilities (Fig. 1). In the past decade, the most common application for SBI has been diagnostic analysis of ex vivo specimens (i.e., point-of-care testing), which has utilized smartphones in a variety of microscopy and microfluidic detection schemes.1 – 4 SBI is also frequently proposed for noninvasive monitoring and diagnosis of externally accessible tissues, particularly in dermatological applications.5 More recently, SBI for minimally invasive procedures and treatment guidance has also been reported, including photodynamic therapy (PDT),6 – 9 endoscopy,10 – 13 in vivo microscopy,14 – 17 and surgery.18 – 22 As ex vivo diagnostic applications have been extensively reviewed elsewhere,1 – 4 this review focuses on SBI systems for real-time tissue imaging applications (i.e., in vivo monitoring, diagnosis, and treatment guidance). However, recent developments in ex vivo diagnostic system designs, which may have relevance in tissue imaging applications are also discussed for comparison and contrast.

15 July 2019 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
KKKathryn A. Kundrod
Kathryn A. Kundrod
CSChelsey A. Smith
Chelsey A. Smith
BHBrady Hunt
Brady Hunt
RSRichard A. Schwarz
Richard A. Schwarz
KSKathleen Schmeler
Kathleen Schmeler
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
Introduction: Cervical cancer mortality rates remain high in low- and middle-income countries (LMICs) and other medically underserved areas due to challenges with implementation and sustainability of routine screening, accurate diagnosis, and early treatment of preinvasive lesions. Areas covered: In this review, we first discuss the standard of care for cervical cancer screening and diagnosis in high- and low-resource settings, biomarkers that correlate to cervical precancer and cancer, and needs for new tests. We review technologies for screening and diagnosis with a focus on tests that are already in use in LMICs or have the potential to be adapted for use in LMICs. Finally, we provide perspectives on the next five years of technology development for improved cervical cancer screening and diagnosis in LMICs. Expert opinion: Innovation toward improved molecular and imaging tests is needed to enable effective, affordable see-and-treat approaches to detect and treat cervical precancer in a single visit. Current molecular tests remain too complex and/or costly for widespread use. Especially with imaging tests, decision support may improve performance of new technologies.

16 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMeaghan Bond
Meaghan Bond
BHBrady Hunt
Brady Hunt
BFBailey Flynn
Bailey Flynn
PHPetri Huhtinen
Petri Huhtinen
RWRussell Ware
Russell Ware
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
A rapid test to identify patients with sickle cell disease could have important benefits in low-resource settings. Sickle cell anemia (SCA) affects about 300,000 newborns each year, the majority of whom are born in sub-Saharan Africa. Low-cost therapies are available to treat SCA, but most countries in sub-Saharan Africa lack robust neonatal screening programs needed to identify patients in need of treatment. To address this need, we developed and evaluated a competitive lateral flow assay that identifies patients with SCA (genotype HbSS) in 15 minutes using undiluted whole blood. A small volume of blood (0.5 μL– 3 μL) is mixed with antibody-coated blue latex beads in a tube and applied to the strip. Strips are then placed in a well of running buffer and allowed to run for 10 minutes. Laboratory evaluation with samples containing different proportions of hemoglobin A (HbA) and hemoglobin S (HbS) indicated that the test should enable identification of SCA patients but not persons with sickle cell trait (SCT). We evaluated the test using 41 samples from individuals with SCA, SCT, and normal blood. With visual inspection or quantitative analysis, we found a 98% accuracy when differentiating SCA from normal and SCT samples as a group (90% sensitivity and 100% specificity for identifying SCA). This work demonstrates important steps towards making a lateral flow test for hemoglobinopathies more appropriate for point-of-care use; further work is needed before the test is appropriate for clinical use.

26 October 2022 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
BHBrady Hunt
Brady Hunt
GGGobind S. Gill
Gobind S. Gill
DADaniel A. Alexander
Daniel A. Alexander
SSSamuel S. Streeter
Samuel S. Streeter
DGDavid J. Gladstone
David J. Gladstone
RZRongxiao Zhang
Rongxiao Zhang

3 April 2021 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
BHBrady Hunt
Brady Hunt
JFJosé Humberto Tavares Guerreiro Fregnani
José Humberto Tavares Guerreiro Fregnani
DBDavid Brenes
David Brenes
RSRichard A. Schwarz
Richard A. Schwarz
MSMila P. Salcedo
Mila P. Salcedo
RRRebecca Richards-Kortum
Rebecca Richards-Kortum

31 May 2018 in Cancer Prevention Research
Verified
Journal Article
Open access
PDF file
BHBrady Hunt
Brady Hunt
JFJosé Humberto Tavares Guerreiro Fregnani
José Humberto Tavares Guerreiro Fregnani
RSRichard A. Schwarz
Richard A. Schwarz
NPNaitielle Pantano
Naitielle Pantano
STSuelen Tesoni
Suelen Tesoni
RRRebecca Richards-Kortum
Rebecca Richards-Kortum
Cervical cancer is a leading cause of death in underserved areas of Brazil. This prospective randomized trial involved 200 women in southern/central Brazil with abnormal Papanicolaou tests. Participants were randomized by geographic cluster and referred for diagnostic evaluation either at a mobile van upon its scheduled visit to their local community, or at a central hospital. Participants in both arms underwent colposcopy, in vivo microscopy, and cervical biopsies. We compared rates of diagnostic follow-up completion between study arms, and also evaluated the diagnostic performance of in vivo microscopy compared with colposcopy. There was a 23% absolute and 37% relative increase in diagnostic follow-up completion rates for patients referred to the mobile van (102/117, 87%) compared with the central hospital (53/83, 64%; P = 0.0001; risk ratio = 1.37, 95% CI, 1.14–1.63). In 229 cervical sites in 144 patients, colposcopic examination identified sites diagnosed as cervical intraepithelial neoplasia grade 2 or more severe (CIN2+; 85 sites) with a sensitivity of 94% (95% CI, 87%–98%) and specificity of 50% (95% CI, 42%–58%). In vivo microscopy with real-time automated image analysis identified CIN2+ with a sensitivity of 92% (95% CI, 84%–97%) and specificity of 48% (95% CI, 40%–56%). Women referred to the mobile van were more likely to complete their diagnostic follow-up compared with those referred to a central hospital, without compromise in clinical care. In vivo microscopy in a mobile van provides automated diagnostic imaging with sensitivity and specificity similar to colposcopy. Cancer Prev Res; 11(6); 359–70. ©2018 AACR.